OptimizeRx (NASDAQ:OPRX) Releases Quarterly Earnings Results, Beats Expectations By $0.17 EPS

OptimizeRx (NASDAQ:OPRX) posted its earnings results on Thursday. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.17, FiscalAI reports. The business had revenue of $26.07 million during the quarter, compared to analyst estimates of $23.83 million. OptimizeRx had a positive return on equity of 4.50% and a negative net margin of 9.42%. OptimizeRx updated its FY 2026 guidance to EPS and its FY 2025 guidance to EPS.

OptimizeRx Stock Down 17.4%

NASDAQ OPRX traded down $3.29 on Friday, hitting $15.65. 1,013,794 shares of the stock traded hands, compared to its average volume of 372,301. The company has a current ratio of 2.57, a quick ratio of 2.57 and a debt-to-equity ratio of 0.21. The stock has a 50-day moving average of $18.87 and a 200 day moving average of $15.15. OptimizeRx has a twelve month low of $3.78 and a twelve month high of $22.25. The company has a market capitalization of $290.54 million, a P/E ratio of -28.98 and a beta of 1.24.

Insider Buying and Selling at OptimizeRx

In related news, CEO Stephen L. Silvestro sold 1,620 shares of the company’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $18.75, for a total transaction of $30,375.00. Following the completion of the transaction, the chief executive officer directly owned 188,916 shares in the company, valued at $3,542,175. This represents a 0.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Patrick D. Spangler sold 11,120 shares of the firm’s stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $17.49, for a total value of $194,488.80. Following the completion of the sale, the director owned 44,215 shares in the company, valued at $773,320.35. The trade was a 20.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 5.60% of the stock is owned by insiders.

Institutional Trading of OptimizeRx

A number of large investors have recently modified their holdings of OPRX. BNP Paribas Financial Markets boosted its stake in OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after purchasing an additional 2,215 shares during the period. Quantbot Technologies LP bought a new stake in shares of OptimizeRx during the second quarter valued at approximately $44,000. American Century Companies Inc. grew its holdings in OptimizeRx by 52.5% in the 2nd quarter. American Century Companies Inc. now owns 24,069 shares of the company’s stock worth $325,000 after buying an additional 8,286 shares in the last quarter. Rhumbline Advisers grew its holdings in OptimizeRx by 29.9% in the 2nd quarter. Rhumbline Advisers now owns 36,082 shares of the company’s stock worth $487,000 after buying an additional 8,297 shares in the last quarter. Finally, WINTON GROUP Ltd acquired a new stake in OptimizeRx in the 2nd quarter valued at approximately $286,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. UBS Group set a $23.00 price target on OptimizeRx in a report on Friday, October 10th. Stifel Nicolaus raised their price target on shares of OptimizeRx from $16.00 to $18.00 and gave the company a “buy” rating in a report on Friday, August 8th. JMP Securities boosted their price objective on shares of OptimizeRx from $20.00 to $23.00 and gave the stock a “market outperform” rating in a report on Friday, October 10th. Zacks Research downgraded OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 7th. Finally, Roth Capital reiterated a “buy” rating on shares of OptimizeRx in a research note on Friday, August 8th. Nine research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $14.45.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.